Peptides as drug candidates against Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 475-481

  Gozes, Illana ^a   Spier, Avron D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

NAP activity dependent neuroprotective factor (ADNF); Vasoactive intestinal peptide activity dependent neuroprotective protein (ADNP)

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ACTIVITY DEPENDENT NEUROPROTECTIVE FACTOR; ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; ACTIVITY DEPENDENT NEUROTROPHIC FACTOR 14; ACTIVITY DEPENDENT NEUROTROPHIC FACTOR 9; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ASPARAGYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; BETA SECRETASE; DOPAMINE; ETHYLCHOLINE MUSTARD AZIRIDINIUM; EXCITOTOXIN; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; MEMBRANE METALLOENDOPEPTIDASE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENT; NEUROTOXIN; SERYLALANYLLEUCYLLEUCYLARGINYLSERYLISOLEUCYLPROLYLALANINE; TAU PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VALYLLEUCYLGLYCYLGLYCYLGLYCYLSERYLALANYLLEUCYLARGINYLSERYLISOLEUCYLPROLYLAL ANINE; VASOACTIVE INTESTINAL POLYPEPTIDE; VIRUS ENVELOPE PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEGRADATION; FETAL ALCOHOL SYNDROME; HEAD INJURY; HUMAN; KNOCKOUT MOUSE; MOLECULAR STABILITY; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT; REVIEW; RISK FACTOR; SENILE PLAQUE; STROKE; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

EID: 0036660254     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10103     Document Type: Review

References (66)

1. Ashur-Fabian O, Giladi E, Furman S, Steingart BA, Wollman Y, Fridkin M, Brenneman DE, Gozes I. 2001. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci Lett 307:167-170.
2. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I. 1999. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293.
3. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E. 2000. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injured mice. J Pharmacol Exp Ther 296:57-63.
4. Birmingham K, Frantz S. 2002. Set back to Alzheimer vaccine studies. Nat Med 8:199-200.
5. Blondel O, Collin C, McCarran B, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RDG. 2000. A glia-derived signal regulating neuronal differentiation. J Neurosci 20:8012-8020.
6. Brenneman DE, Eiden LE. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 83:1159-1162.
7. Brenneman DE, Gozes I. 1996. A femtomolar-acting neuroprotective peptide. J Clin Invest 97:2299-2307.
8. Brenneman DE, Hauser J, Neale E, Bubinraut S, Fridkin M, Davidson A, Gozes I. 1998. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285:619-627.
9. Clement A, Walsh DM, Williams CH, Allsop D. 1993. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid b/A4 peptide. Neurosci Lett 161:17-20.
10. Counts SE, Perez SE, Kahl U, Bartfai T, Bowser BP, Deecher DC, Mash DC, Crawley JN, Mufson EJ. 2001. Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev 7:445-470.
11. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC. 1999. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56:1135-1140.
12. Croom J, Taylor IL. 2001. Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship? J Inorg Biochem 87:51-56.
13. Eldar-Finkelman H. 2002. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8:126-132.
14. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, Lee JP, Mantyh PW, Maggio JE. 2000. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39:6288-6295.
15. Frenkel D, Solomon B. 2001. Towards Alzheimer's beta-amyloid vaccination. Biologicals 29:243-247.
16. Glazner GW, Boland A, Dresse AE, Brenneman DE, Gozes I, Mattson MP. 1999. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J Neurochem 73:2341-2347.
17. Glazner GW, Camandola S, Mattson MP. 2000. Nuclear factor-kappaB mediates the cell survival-promoting action of activity dependent neurotrophic factor peptide-9. J Neurochem 75:101-108.
18. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495.
19. Gozes I, Brenneman DE. 1989. VIP molecular biology and neurobiological function. Mol Neurobiol 3:201-236.
20. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. 1996. Novel neuroprotective strategy for Alzheimer's disease: inhalation of a fatty neuropeptide. Proc Natl Acad Sci USA 93:427-432.
21. Gozes I, Brenneman DE 1996. Activity-dependent neurotrophic factor (ADNF): an extra-cellular neuroprotective chaperonin? J Mol Neurosci 7:235-244.
22. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. 1997a. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimer's disease. J Neurobiol 33:329-342.
23. Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, Warren D, Hauser J, Brenneman DE. 1997b. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Dev Brain Res 99:167-175.
24. Gozes I, Fridkin M, Hill JM, Brenneman DE. 1999a. Pharmaceutical VIP: prospects and problems. Curr Med Chem 6:1019-1034.
25. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. 1999b. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc Natl Acad Sci USA 96:4143-4148.
26. Gozes I, Ciladi E, Pinhasov A, Bardea A, Brenneman DE. 2000. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a watermaze. J Pharmacol Exp Ther 293:1091-1098.
27. Gozes I, Brenneman DE. 2000. A new concept in neuroprotection. J Mol Neurosci 14:61-68.
28. Gozes I. 2001. Neuroprotective peptide drug delivery and development: potential new therapeutics. TINS 24:700-705.
29. Gozes I, Brenneman DE, Geppetti P, Kastin AJ, Mains RE, Moody TW, Seroogy K, Spier AD, Zimmermann M. 2001a. Neuropeptides: brain messengers of many faces. Trends Neurosci 24:687-690.
30. th Oholo conference: the blood brain barrier drug delivery and brain pathology. New York: Kluwer Academic/Plenum Publishers, p 363-370.
31. Gozes I. 2002. Special Issue: Neuroeptides. J Mol Neurosci 18:1-165.
32. Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE. 2002. NAP: a neuroprotective peptide. J Mol Neurosci 19:175-178.
33. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P. 1997. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 100:390-397.
34. Gressens P, Marret S, Bodenant C, Schwendimann L, Evrard P. 1999. Activity-dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase kinase activation to protect the developing mouse brain against excitotoxicity. J Mol Neurosci 13:199-210.
35. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, and Mattson MP. 1999. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 96:4125-4130.
36. Guo ZH, Mattson MP. 2000. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex 10:50-57.
37. Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E, Abe Y, Kita Y, Nishimoto I. 2001. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J Neurosci 21:9235-9245.
38. Hetenyi C, Kortvelyesi T, Penke B. 2002. Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease. Bioorg Med Chem 10:1587-1593.
39. Iwata N, Tsubuld S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
40. Jarrett, JT, Lansbury PT. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scarpie? Cell 73:1055-1058.
41. Jhamandas JH, Harris KH, MacTavish D, Jassar BS. 2002. Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer's disease. J Neurophysiol 87:696-704.
42. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I. 2002. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33:1085-1092.
43. Leslie M. (Gerhold, L.) 2002. Brain saver: compound might shield neurons during stroke. Science 14, April 10 [available online at http://sageke.sciencemag.org].
44. Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ. 2002. A liposome-based therapeutic vaccine against beta-amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci USA 99:2332-2337.
45. Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R. 2001. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides 22:2105-2112.
46. Offen D, Sherld Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. 2000. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262.
47. Papasozomenos SCh, Shanavas A. 2002. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 99:1140-1145.
48. Pedersen WA, Wan R, Zhang P, Mattson MP. 2002. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci 22:404-412.
49. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. 1999. B-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain-barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39:371-382.
50. Pompei P, Severini R, Pediconi D, Angeletti M, Eleuteri A, Fattoretti P, Bertoni-Freddari C, Fioretti E. 2001. Regulation of preprotachykinin-A gene expression in an animal model of Alzheimer's disease. J Histochem Cytochem 49:1469-1470.
51. Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S, Maggirwar SB. 2001. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem 78:874-889.
52. Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I. 2002. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci 18:37-45.
53. Sigalov E, Fridkin M, Brenneman DE, Gozes I. 2000. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells. A model for ischemic/hypoxic injury. J Mol Neurosci 15:147-154.
54. Schenk D, Seubert P, Ciccarelli RB. 2001. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol 20:679-681.
55. Sisodia SS, Annaert W, Kim SH, De Strooper B. 2001. Gamma-secretase: never more enigmatic. Trends Neurosci 24(Suppl): S2-6.
56. Sisioda SS, Tanzi RE. 2001. Special Issue: Alzheimer's disease. J Mol Neurosci 17:99-270.
57. Soto C, Branes MC, Alvarez J, Inestrosa NC. 1994. Structural determinants of the Alzheimer's amyloid beta-peptide J Neurochem 63:1191-1198.
58. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. 1998. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-826.
59. Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. 2001. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297:774-779.
60. Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I. 2000. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 15:131-145.
61. Vassar R. 2001. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci 17:157-170.
62. White DM, Walker S, Brenneman DE, Gozes I. 2000. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res 868:31-38.
63. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH. 2002. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci 22:10-20.
64. Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, Atlas R, Brenneman DE, Gozes I. 1999. A femtomolar-acting neuroprotective peptide induces intracellular increases in heat shock protein 60: a potential neuroprotective mechanism. Neurosci Lett 264:9-12.
65. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I. 2001. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 276:708-714.
66. Zemlyak I, Furman S, Brenneman DE, Gozes I. 2000. A novel peptide (NAP) prevents death in enriched neuronal cultures. Regul Pept 96:39-43.